{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:43:05Z","timestamp":1790660585263,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.vaccine.2024.06.026","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T23:26:15Z","timestamp":1719444375000},"page":"126059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10\u201360 year-old demographic"],"prefix":"10.1016","volume":"42","author":[{"given":"Fei","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leitai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-6341","authenticated-orcid":false,"given":"Li","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.06.026_b0005","series-title":"Rabies and rabies vaccine [M]","first-page":"189","author":"Yu","year":"2009"},{"key":"10.1016\/j.vaccine.2024.06.026_b0010","series-title":"Application and development of vaccines [M]","first-page":"417","author":"Tao","year":"2009"},{"key":"10.1016\/j.vaccine.2024.06.026_b0015","first-page":"146","article-title":"Investigation of the immunization effectiveness of dog rabies vaccines in Zhongshan City from 2010 to 2021","volume":"05","author":"Chen","year":"2022","journal-title":"Chin J Anim Infect Diseases"},{"issue":"2","key":"10.1016\/j.vaccine.2024.06.026_b0020","first-page":"168","article-title":"Analysis of the epidemiological characteristics of rabies in China from 2007 to 2018","volume":"35","author":"Mou","year":"2021","journal-title":"Chin J Exp Clin Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.06.026_b0025","first-page":"131","article-title":"Analysis of the epidemiological characteristics of rabies in China from 2016 to 2018","volume":"42","author":"Liu","year":"2021","journal-title":"Chin J Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2024.06.026_b0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/dnares\/dsu029","article-title":"The genome landscape of the african green monkey kidney-derived Vero cell line","volume":"21","author":"Osada","year":"2014","journal-title":"DNA Res"},{"key":"10.1016\/j.vaccine.2024.06.026_b0035","first-page":"100","article-title":"Research progress on rabies vaccines","volume":"01","author":"Li","year":"2017","journal-title":"Biotechnol Ind"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2024.06.026_b0040","first-page":"439","article-title":"Reactogenicity and immunogenicity of the newly developed purified chick embryo cell (PCEC)-rabies vaccine in man","volume":"265","author":"Scheiermann","year":"1987","journal-title":"Z Bakteriol Mikrobiol Hyg A"},{"issue":"2","key":"10.1016\/j.vaccine.2024.06.026_b0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/21645515.2020.1778408","article-title":"Immunogenicity and safety of purified Vero cell-cultured rabies vaccine under Zagreb 2\u20131-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial","volume":"17","author":"Shen","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2024.06.026_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1279770","article-title":"Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects","volume":"13","author":"Shi","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2024.06.026_b0055","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1080\/21645515.2021.1880200","article-title":"Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post- exposure subjects: a post-marketing, parallel control clinical trial","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2024.06.026_b0060","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4161\/hv.28420","article-title":"Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China","volume":"10","author":"Hu","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2024.06.026_b0065","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.4161\/21645515.2014.972773","article-title":"A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2\u20131-1) compared with the Essen regimen in Chinese adults","volume":"10","author":"Ma","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2024.06.026_b0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.biologicals.2005.06.005","article-title":"The influence of homologous vs.heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays","volume":"33","author":"Moore","year":"2005","journal-title":"Biologicals"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2024.06.026_b0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.virusres.2006.10.011","article-title":"A molecular epidemiological study targeting the glycoprotein gene of rabies virus isolates from China","volume":"124","author":"Meng","year":"2007","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/j.vaccine.2024.06.026_b0080","first-page":"22","article-title":"Analysis and comparison of the glycoprotein gene sequences of four rabies virus strains in China","volume":"15","author":"Tang","year":"2000","journal-title":"Virol Sin"},{"issue":"8","key":"10.1016\/j.vaccine.2024.06.026_b0085","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1080\/21645515.2021.1880200","article-title":"Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: a post-marketing, parallel control clinical trial","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2024.06.026_b0090","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/21645515.2016.1230260","article-title":"Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2\u20131-1 or 5-dose essen regimen in chinese adults aged 50 and above","volume":"13","author":"Wang","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"10.1016\/j.vaccine.2024.06.026_b0095","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1016\/j.vaccine.2022.06.040","article-title":"Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: a randomised phase II pre-exposure prophylaxis study","volume":"40","author":"Pichon","year":"2022","journal-title":"Vaccine"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2024.07.029","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400700X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400700X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:43:22Z","timestamp":1773182602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2400700X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":19,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0264410X2400700X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10\u201360 year-old demographic","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126059"}}